Browsing Centre for Neuroscience, Surgery and Trauma by Subject "Immunologic Factors"
Now showing items 1-5 of 5
-
Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.
(2017-09-12)OBJECTIVE: To evaluate 5-year efficacy and safety of alemtuzumab in patients with active relapsing-remitting multiple sclerosis and inadequate response to prior therapy. METHODS: In the 2-year Comparison of Alemtuzumab and ... -
CSF neurofilament light chain testing as an aid to determine treatment strategies in MS.
(2020-11)OBJECTIVE: To evaluate the use of CSF neurofilament light chain (NfL) measurements in clinical practice as well as their effect on treatment strategies and outcomes in patients with MS. METHODS: This was an observational ... -
Marked neutropenia: Significant but rare in people with multiple sclerosis after alemtuzumab treatment.
(2017-11)BACKGROUND: Alemtuzumab is a CD52-specific monoclonal antibody that markedly depletes T and B lymphocytes and inhibits relapsing multiple sclerosis (MS). However, polymorphonuclear neutrophils also express CD52 and can be ... -
Neuromyelitis optica spectrum disorder presenting as rhomboencephalitis.
(2018-05-23)Rhomboencephalitis, at least in its acute phase, is often a severely disabling syndrome, and can be life threatening. A range of underlying conditions can lead to this clinical syndrome. Rapid diagnosis to initiate treatment ... -
Switching patients at high risk of PML from natalizumab to another disease-modifying therapy.
(2016-10)There are several options for switching people with multiple sclerosis (MS) who are at high risk of developing progressive multifocal leukoencephalopathy (PML) from natalizumab to alemtuzumab. However, some of these have ...